Market revenue in 2023 | USD 23.6 million |
Market revenue in 2030 | USD 39.2 million |
Growth rate | 7.5% (CAGR from 2023 to 2030) |
Largest segment | Mrna reprogramming |
Fastest growing segment | MRNA Reprogramming |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Sendai Virus-based Reprogramming, MRNA Reprogramming, Episomal Reprogramming |
Key market players worldwide | Thermo Fisher Scientific Inc, Merck KGaA, Bio-Techne Corp, ReproCELL, Lonza Group Ltd, FUJIFILM Holdings Corp, Astellas Pharma Inc, Allele Biotech, Alstem, STEMCELL Technologies |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to cell reprogramming market will help companies and investors design strategic landscapes.
Mrna reprogramming was the largest segment with a revenue share of 33.47% in 2023. Horizon Databook has segmented the Germany cell reprogramming market based on sendai virus-based reprogramming, mrna reprogramming, episomal reprogramming covering the revenue growth of each sub-segment from 2018 to 2030.
Germany accounted for a significant revenue share of Europe cell reprogramming market due to presence of a substantial number of providers offering cell reprogramming and initiatives undertaken by them to expand their businesses.
These companies are undertaking numerous business initiatives to expand their geographic presence. For instance, in June 2021, Catalent, a U.S.-based company, announced that it plans to acquire RheinCell Therapeutics GmbH. RheinCell manufactures and develops GMP-grade human iPSCs.
This strategic acquisition enhanced the manufacturing capabilities and development of Catalent's custom cell therapy process by incorporating proprietary GMP cell lines for iPSC-based therapies.
Horizon Databook provides a detailed overview of country-level data and insights on the Germany cell reprogramming market , including forecasts for subscribers. This country databook contains high-level insights into Germany cell reprogramming market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account